Lornoxicam Tablets 1

2 ロルノキシカム錠

3

4 Lornoxicam Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of lornox-5 icam (C₁₃H₁₀ClN₃O₄S₂: 371.82). 6

7 Method of preparation Prepare as directed under Tablets, 8 with Lornoxicam.

9 Identification Take an amount of powdered Lornoxicam 10 Tablets, equivalent to 4 mg of Lornoxicam, add 70 mL of a solution of hydrochloric acid in methanol (9 in 10,000), son-11 12 icate, and add a solution of hydrochloric acid in methanol (9 in 10,000) to make 100 mL. Centrifuge this solution, to 5 mL 13 of the supernatant liquid add a solution of hydrochloric acid 14 in methanol (9 in 10,000) to make 20 mL. Determine the ab-15 sorption spectrum of this solution as directed under Ultravi-16 olet-visible Spectrophotometry <2.24>: it exhibits maximum 17 between 359 nm and 363 nm. 18 19 Purity Related substances-Take a quantity of Lornoxicam 20 Tablets, equivalent to 4 mg of Lornoxicam, add exactly 20

21 mL of the mobile phase, and sonicate. Centrifuge this solu-22 tion, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 40 mg of Lornoxicam RS, 23 previously dried at 105°C for 4 hours, dissolve in acetonitrile 24 25 to make exactly 200 mL. Pipet 1 mL of this solution, add the 26 mobile phase to make exactly 100 mL, and use this solution

27 as the standard solution. Perform the test with exactly 10 μ L 28 each of the sample solution and standard solution as directed

29 under Liquid Chromatography <2.01>according to the fol-

30 lowing conditions. Determine each peak area by the auto-31 matic integration method, and calculate the amounts of the

32 related substances by the following equation: the amount of

33 related substance B having the relative retention time of

34 about 0.13 to lornoxicam is not more than 2.0%, the amount 35 of related substance TA having the relative retention time of

about 0.15 is not more than 1.2%, the amount of related sub-36

37 stance TB having the relative retention time of about 0.21 is

38 not more than 2.0%, the amount of related substance TC hav-

39 ing the relative retention time of about 0.25 is not more than

40 3.0%, the amount of related substance TD having the relative

41 retention time of about 0.36 is not more than 2.0%, and the

amount of the related substances other than the peak of lor-42

noxicam, the related substances A having the relative reten-43 44 tion time of about 0.4 to lornoxicam and the peaks mentioned

45 above is not more than 2.0%. Furthermore, the total amount

46 of the related substances is not more than 5.0%. For the peak

47 areas of the related substances TA and TC, multiply their cor-

48 rection factors 0.6 and 1.5, respectively. Amount (%) of related substance (%) $=M_{\rm S} \times A_{\rm T}/A_{\rm S} \times 1/40$

51 M_S: Amount (mg) of Lornoxicam RS taken

 $A_{\rm T}$: Peak area of each related substance obtained from the sample solution

As: Peak area of lornoxicam obtained from the standard solution

56 Operating conditions-

49

50

52

53

54

55

57 Detector: An ultraviolet absorption photometer (wave-58 length: 280 nm).

59 Column: A stainless steel column 4 mm in inside diameter 60 and 15 cm in length, packed with octadecylsilanized silica gel 61 for liquid chromatography (5 μ m in particle diameter).

62 Column temperature: A constant temperature of about 63 50°C.

64 Mobile phase: Dissolve 4.2 g of tetra-n-butylammonium 65 bromide, 4.6 g of disodium hydrogen phosphate dodecahy-66 drate and 4.4 g of potassium dihydrate phosphate in 1300 mL 67 of water, and add 700 mL of acetonitrile for liquid chroma-68 tography.

69 Flow rate: Adjust so that the retention time of lornoxicam 70 is about 20 minutes.

71 Time span of measurement: About 1.5 times as long as the 72 retention time of lornoxicam, beginning after the solvent 73 peak.

74 System suitability-

75 System performance: When the procedure is run with 10 μ L of the standard solution under the above operating condi-76 77 tions, the number of theoretical plates and symmetry factor 78 of the peak of lornoxicam are not less than 10,000 and not 79 more than 1.5, respectively..

80 System repeatability: When the test is repeated 6 times 81 with 10 μ L of the standard solution under the above operating 82 conditions, the relative standard deviation of the peak area of 83 lornoxicam is not more than 2.0%.

84 Loss on drying <2.41> Not more than 2.0% (in vacuum, phosphorus (V) oxide, 24 hours). Take a number of Lornox-85 86 icam Tablets, equivalent to 24 mg of Lornoxicam, powder immediately, and perform the test. 87

88 Uniformity of dosage units <6.02> Perform the test ac-89 cording to the following method: it meets the requirement of 90 the Content uniformity test.

91 To 1 tablet of Lornoxicam Tablets add V/10 mL of water, 92 and sonicate. Add 3V/5 mL of a mixture of acetonitrile and 93 methanol (1:1), sonicate, then add a mixture of acetonitrile 94 and methanol (1:1) to make exactly V mL so that each mL 95 contains about 80 μ g of lornoxicam (C₁₃H₁₀ClN₃O₄S₂), and 96 centrifugate. Pipet 10 mL of the supernatant liquid, add ex-97 actly 1 mL of the internal standard solution, then add the mo-

98 bile phase to make 20 mL, and use this solution as the sample 99 solution. Separately, weigh accurately about 40 mg of Lor-

100 noxicam RS, previously dried 105°C for 4 hours, dissolve in 101 a mixture of acetonitrile and methanol (1:1) to make exactly

102 200 mL. Pipet 20 mL of this solution, add 5 mL of water, and

103 add a mixture of acetonitrile and methanol (1:1) to make ex-

actly 50 mL. Pipet 10 mL of this solution, add exactly 1 mL 104

of the internal standard solution, then add the mobile phase 105

to make 20 mL, and use this solution as the standard solution. 106

107 Perform the test with 10 μ L each of the sample solution and

standard solution as directed under Liquid Chromatography 108

109 <2.01> according to the following conditions. and calculate 110 the ratios, $Q_{\rm T}$ and $Q_{\rm S}$, of the peak area of lornoxicam to that

111 of the internal standard.

Amount (mg) of lornoxicam (C₁₃H₁₀ClN₃O₄S₂) 112 $=M_{\rm S} \times Q_{\rm T}/Q_{\rm S} \times V/500$ 113

114 M_S: Amount (mg) of Lornoxicam RS taken

165 115 Internal standard solution-A solution of diphenylamine in

the mobile phase (1 in 4000). 116

117 Operating conditions-

118 Proceed as directed in the operating conditions in the As-119 say.

120 System suitability—

171 121 System performance: When the procedure is run with 10 122 μ L of the standard solution under the above operating conditions, lornoxicam and the internal standard are eluted in this 123 124 order with the resolution being not less than 6.

125 System repeatability: When the test is repeated 6 times 126 with 10 μ L of the standard solution under the above operating 127 conditions, the relative standard deviation of the ratio of the 128 peak area of lornoxicam to that of the internal standard is not 129 more than 1.5%.

Dissolution <6.10> When the test is performed at 75 revo-130 lutions per minute according to the Paddle method, using 900 131 132 mL of water as the dissolution medium, the dissolution rate 182 133 in 10 minutes of Lornoxicam Tablets is not less than 80%.

184 134 Prepare the sample solution within 1 hour. Start the test 135 with 1 tablet of Lornoxicam Tablets, withdraw not less than 185 186 20 mL of the medium at the specified minute after starting 136 the test, and filter through a membrane filter with a pore size 137 188 not exceeding 0.45 μ m. Discard not less than 10 mL of the 138 first filtrate, pipet V mL of the subsequent filtrate, add the 189 139 140 mobile phase to make exactly V' mL so that each mL contains 191 141 about 1.1 μ g of lornoxicam (C₁₃H₁₀ClFN₃O₄S₂), and use this 142 solution as the sample solution. Separately, weigh accurately 192 143 about 40 mg of lornoxicam for assay, previously dried 105°C 144 for 4 hours, dissolve in acetonitrile to make exactly 200 mL. 145 Pipet 2 mL of this solution, add the mobile phase to make 146 exactly 100 mL. Pipet 5 mL of this solution, add the mobile 147 phase to make exactly 20 mL, and use this solution as the 148 standard solution. Perform the test with exactly 100 μ L each

149 of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following 150 151 conditions. and determine the peak areas, A_T and A_S , of lor-152 noxicam in each solution.

153 Dissolution rate (%) with respect to the labeled amount of lornoxicam (C₁₃H₁₀ClFN₃O₄S₂)

 $=M_{\rm S} \times A_{\rm T}/A_{\rm S} \times V'/V \times 1/C \times 9/4$

M_S: Amount (mg) of lornoxicam for assay taken

C: Labeled amount (mg) of lornoxicam (C13H10ClFN3O4S2) in 1 tablet

159 Operating conditions-

154

155

156 157

158

160

161

163

164

166

167

168

169

170

172

173

174

175

176

177

178

179

180

181

183

187

190

193

194

195

Proceed as directed in the operating conditions in the Assay.

162 System suitability—

> System performance: When the procedure is run with 100 μ L of the standard solution under the above operating conditions, the theoretical plates and the symmetry factor of the peak area of lornoxicam are not less than 1500 and not more than 2.0, respectively.

> System repeatability: When the test is repeated 6 times with 100 μ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of lornoxicam is not more than 1.5%.

> Assay To 15 tablets of Lornoxicam Tablets, add V/10 mL of water, and sonicate. Add 7V/10 of a mixture of acetonitrile and methanol (1:1), sonicate, then add a mixture of acetonitrile and methanol (1:1) to make exactly V mL so that each mL contains about 120 μ g of lornoxicam (C₁₃H₁₀ClFN₃O₄S₂), and centrifuge. Pipet 5 mL of the supernatant liquid, add exactly 1 mL of the internal standard solution, then add the mobile phase to make 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 60 mg of Lornoxicam RS, previously dried at 105°C or 4 hours, and dissolve in a mixture of acetonitrile and methanol (1:1) to make exactly 200 mL. Pipet 20 mL of this solution, add 5 mL of water, and add a mixture of acetonitrile and methanol (1:1) to make exactly 50 mL. Pipet 5 mL of this solution, add exactly 1 mL of the internal standard solution, then add the mobile phase to make 20 mL, and use this solution as the standard solution. Perform the test with 10 μ L each of the sample solution and standard solution as directed under Liquid chromatography <2.01> according to the following conditions, and calculate the ratios, $Q_{\rm T}$ and $Q_{\rm S}$, of the peak area of lornoxicam to that of the internal standard.

Amount (mg) of lornoxicam (C13H10ClFN3O4S2) in 1 tablet $=M_{\rm S} \times Q_{\rm T}/Q_{\rm S} \times V/7500$

M_S: Amount (mg) of Lornoxicam RS taken


196 Internal standard solution-A solution of diphenylamine in 197 the mobile phase (1 in 5000).

- 198 Operating conditions-
- Detector: An ultraviolet absorption photometer (wave-length: 295 nm).
- 201 Column: A stainless steel column 4 mm in inside diameter 236
- 202 and 15 cm in length, packed with octadecylsilanized silica gel
- 203 for liquid chromatography (5 μ m in particle diameter).
- 204 Column temperature: A constant temperature of about 205 50°C.
- 206Mobile phase: A mixture of methanol, a solution of sodium207lauryl sulfate (1 in 90) and phosphoric acid (550:450:1).
- 208 Flow rate: Adjust so that the retention time of lornoxicam
- 209 is about 4 minutes.
- 210 System suitability-
- 211 System performance: When the procedure is run with 10
- 212 μ L of the standard solution under the above operating condi-
- 213 tions, lornoxicam and the internal standard are eluted in this
- 214 order with the resolution being not less than 6.
- 215 System repeatability: When the test is repeated 6 times
- 216 with 10 μ L of the standard solution under the above operating
- 217 conditions, the relative standard deviation of the ratio of the
- $218 \quad \text{peak area of lornoxicam to that of the internal standard is not}$
- 219 more than 1.5%.
- 220 Containers and storage Containers-Tight containers.
- 221 Others
- 222 Related substances A and B: Refer to them described in Lor-
- 223 noxicam.

226

229

- 224 Related substance TA:
- 225 (Pyridin-2-yl)oxamic acid




- 227 Related substance TB:
- 228 5-Chloro-3-sulfinothiophene-2-carboxylic acid

- 230 Related substance TC:
- 231 5-Chloro-3-sulfothiophene-2-carboxylic acid

- 232
- 233 Related substance TD:
- 234 5-Chloro-3-(N-methylsulfamoyl)thiophene-2-carboxylic

235 acid



237 Add the following to 9.01 Reference 238 Standards (1):

239 Lornoxicam RS

240